15.10.2012 • NewsAllergangenericslawsuits

US High Court Rejects Allergan's Sanctura Patent Appeal

The U.S. Supreme Court on Monday rejected Allergans appeal of a ruling that favored generic drugmaker Watson Pharmaceuticals over patents related to the treatment of an overactive bladder.

Allergan was challenging a June decision by the U.S. Federal Circuit Court of Appeals that its patents related to Sanctura XR were invalid because the treatment was "obvious," meaning it was highly likely to succeed based on information already known.

The Irvine, California-based company had accused Watson and its partners in a lawsuit of infringing the patents when creating a generic version of its drug, whose sales totaled about $56.8 million in 2011.

In its appeal, Allergan said the decision, if upheld, would set too low a bar for obviousness and could impede the development of "pioneer" drugs because inventors might fear that they were unpatentable.

The Supreme Court, without comment on Monday, refused to hear the case. Justice Samuel Alito did not participate in the court's decision to deny the appeal. The court's order provided no reason.

Overactive bladder afflicts more than 33 million, mostly elderly, Americans, Allergan said.

The case is Allergan Inc et al v. Watson Laboratories Inc, U.S. Supreme Court, No. 12-342.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read